Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2024 | ELECTRA: novel combinations for HR-positive breast cancer with CNS metastases

Eva Ciruelos • 15 Sep 2024
ESMO 2024
Breast Cancer Abemaciclib Elacestrant
ELECTRA

Eva Ciruelos, MD, PhD, Hospital 12 de Octubre, Madrid, Spain, highlights the importance of the Phase Ib/II ELECTRA trial (NCT05386108), which explores new treatment combinations for patients with HER2-positive, HR-positive (HR+/HER2+) breast cancer with CNS metastases. Though less common in this population compared to triple-negative or HER2-positive cases, CNS metastases carry a poor prognosis. The combination of abemaciclib and elacestrant, both capable of crossing the blood-brain barrier, offers a promising therapeutic approach for this difficult-to-treat condition. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Eva Ciruelos

ELECTRA: elacestrant and abemaciclib in patients with ER+, HER2- breast cancer
1:43
ELECTRA: elacestrant and abemaciclib in patients with ER+, HER2- breast cancer
Eva Ciruelos • 15 Sep 2024
DESTINY-Breast12: enhancing outcomes for HR+/HER2+ patients with brain metastases
1:33
DESTINY-Breast12: enhancing outcomes for HR+/HER2+ patients with brain metastases
Eva Ciruelos • 15 Sep 2024
Global collaboration in biomarker-driven clinical trials at ESMO 2024
1:03
Global collaboration in biomarker-driven clinical trials at ESMO 2024
Eva Ciruelos • 15 Sep 2024
PATRICIA: Phase II study of palbociclib, trastuzumab, and endocrine therapy in HER2+ advanced BC
0:44
PATRICIA: Phase II study of palbociclib, trastuzumab, and endocrine therapy in HER2+ advanced BC
Eva Ciruelos • 31 May 2024

Related Videos

ASCENT-04: PFS2 with sacituzumab govitecan and pembrolizumab in PD-L1+ mTNBC
1:12
ASCENT-04: PFS2 with sacituzumab govitecan and pembrolizumab in PD-L1+ mTNBC
Kevin Kalinsky • 31 May 2026
Clinical relevance of PFS2 in metastatic triple-negative breast cancer
1:10
Clinical relevance of PFS2 in metastatic triple-negative breast cancer
Kevin Kalinsky • 31 May 2026
Genomic assays and chemotherapy decisions in node-positive breast cancer
1:35
Genomic assays and chemotherapy decisions in node-positive breast cancer
Kevin Kalinsky • 31 May 2026
ASCENT-07: SG in patients with HER2 IHC0 HR+/HER2- breast cancer
1:30
ASCENT-07: SG in patients with HER2 IHC0 HR+/HER2- breast cancer
Yeon Hee Park • 31 May 2026
The content of VJOncology is intended for healthcare professionals